For research use only. Not for therapeutic Use.
Nidufexor（Cat No.:I019418）is an investigational agonist targeting the farnesoid X receptor (FXR), a key regulator in bile acid metabolism, with potential applications in treating liver diseases, particularly non-alcoholic steatohepatitis (NASH). By activating FXR, Nidufexor modulates lipid and glucose metabolism, reducing hepatic inflammation and fibrosis, which are critical in NASH progression. Known for its favorable pharmacokinetic profile, Nidufexor offers promise in lowering liver enzyme levels and improving liver histology. This selective FXR agonist is under study for its efficacy and safety in combating metabolic-related liver conditions.
| Catalog Number | I019418 |
| CAS Number | 1773489-72-7 |
| Molecular Formula | C₂₇H₂₂ClN₃O₄ |
| Purity | ≥95% |
| Storage | Store at -20°C |
| IUPAC Name | 4-[[benzyl-(8-chloro-1-methyl-4H-chromeno[4,3-c]pyrazole-3-carbonyl)amino]methyl]benzoic acid |
| InChI | InChI=1S/C27H22ClN3O4/c1-30-25-21-13-20(28)11-12-23(21)35-16-22(25)24(29-30)26(32)31(14-17-5-3-2-4-6-17)15-18-7-9-19(10-8-18)27(33)34/h2-13H,14-16H2,1H3,(H,33,34) |
| InChIKey | JYTIXGYXBIBOMN-UHFFFAOYSA-N |
| SMILES | CN1C2=C(COC3=C2C=C(C=C3)Cl)C(=N1)C(=O)N(CC4=CC=CC=C4)CC5=CC=C(C=C5)C(=O)O |
| Reference | [1]. Chianelli D, et al. Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem. 2020 Apr 23;63(8):3868-3880. |
